Hamburg "Guardedly Optimistic" On FDA Budget
This article was originally published in The Pink Sheet Daily
Executive Summary
Addressing FDA's Science Board Advisory Committee, Commissioner Margaret Hamburg says she expects the agency will end up with about the same level of funding as in fiscal 2011.
You may also be interested in...
"Virtual Patients," Medical Countermeasures On FDA Regulatory Science Horizon
The agency is planning a library of validated computer models of how patients respond to medical treatments.
FDA Reorganization Adds "Directorate" Layer, But Sharpens Agency's Focus
Commissioner Margaret Hamburg’s structural reorganization of FDA leaves the current leadership of the drug and biologic review centers intact but adds a new layer of management and accountability between the medical product center directors and the commissioner’s office.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.